TSRA-196 / Tessera Therapeutics, Regeneron - LARVOL DELTA

Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD (GlobeNewswire) - "Tessera recently initiated a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. In this first-in-human, open-label, multi-national study, trial participants will receive a single intravenous administration of TSRA-196 and be followed longitudinally for safety and key biomarkers relevant to AAT expression and function."

Fast track • First-in-human • Orphan drug • Trial status • Alpha-1 Antitrypsin Deficiency